How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,507 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS). (PubMed)

Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS). Active surveillance (AS) is increasingly used to monitor patients with low-risk prostate cancer; however, approximately 50% of AS patients experience disease reclassification requiring definitive treatment and little is known about patient characteristics that modify the risk (...) of reclassification. Obesity may be one of the major contributing factors. The Prostate Cancer Active Lifestyle Study (PALS) is a clinical trial evaluating the impact of weight loss among overweight/obese (Body Mass Index (BMI) ≥ 25 kg/m2) men with clinically localized prostate cancer on AS. Two hundred participants will be randomized to either the PALS intervention, a 6-month structured diet and exercise program adapted from the Diabetes Prevention Program followed by 6 months of maintenance, or control (general

2019 Contemporary clinical trials Controlled trial quality: uncertain

3. Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis (PubMed)

Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis Bone lesions on prostate MRI often raise concern about metastases. This study aimed to evaluate the prevalence of bone metastases on staging prostate MRI and evaluate associations between their MRI features and clinical/pathologic characteristics.Retrospective, IRB-approved study of 3765 patients undergoing prostate MRI for newly diagnosed PCa between 2000 and 2014 (...) . The reference standard to calculate the prevalence of bone metastases was bone biopsy and/or ≥1-year follow-up after MRI. In a subsample of 228 patients, the MRI characteristics of bone lesions were recorded by two radiologists independently. Associations between MRI and clinical/pathologic findings, including National Comprehensive Cancer Network (NCCN) risk categories, were calculated.57/3765 patients (1.5%, 95% CI 1.2-2.0%) had bone metastases. No patient with NCCN low-risk PCa (Gleason < 7, PSA < 10 ng

Full Text available with Trip Pro

2017 Abdominal radiology (New York)

4. Accuracy of gallium-68 prostate-specific membrane antigen positron emission tomography for local staging of prostate cancer: a systematic review and meta-analysis

Accuracy of gallium-68 prostate-specific membrane antigen positron emission tomography for local staging of prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) species); sex (stratified per sex); duration of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease

2019 PROSPERO

5. STABILITY OF A 17-GENE GENOMIC PROSTATE SCORE IN SERIAL TESTING OF MEN ON ACTIVE SURVEILLANCE FOR EARLY STAGE PROSTATE CANCER. (PubMed)

STABILITY OF A 17-GENE GENOMIC PROSTATE SCORE IN SERIAL TESTING OF MEN ON ACTIVE SURVEILLANCE FOR EARLY STAGE PROSTATE CANCER. Genomic testing may improve risk stratification for men with prostate cancer managed with active surveillance (AS). We aimed to characterize the stability and utility of serial genomic test scores in men undergoing serial biopsies during AS.We compiled clinical and disease characteristics of men on AS at an institutional Urologic Outcomes Database. We included patients (...) initially diagnosed with Gleason 3+3 prostate cancer electing AS, who received two 17-gene Genomic Prostate Score (GPS) results. We examined the association between GPS scores and Gleason grade reclassification (≥Gleason 3+4) and definitive treatment using multivariable Cox proportional hazards regression models.We identified 111 men who underwent serial genomic testing. There were 49 (44%) grade reclassification events at median follow-up of 64 months. The mean change in GPS between first and second

2019 Journal of Urology

6. Prostate Cancer?Pretreatment Detection, Surveillance, and Staging

Prostate Cancer?Pretreatment Detection, Surveillance, and Staging Revised 2016 ACR Appropriateness Criteria ® 1 Prostate Cancer–Pretreatment Detection American College of Radiology ACR Appropriateness Criteria ® Prostate Cancer–Pretreatment Detection, Surveillance, and Staging Variant 1: Clinically suspected prostate cancer, no prior biopsy (biopsy naïve). Detection. Radiologic Procedure Rating Comments RRL* TRUS guided biopsy prostate 9 O MRI pelvis without and with IV contrast 7 MRI (...) technique) can be obtained from appropriate suspicious lesions. O MRI pelvis without IV contrast 7 O TRUS prostate 2 O CT abdomen and pelvis with IV contrast 2 ??? CT abdomen and pelvis without IV contrast 2 ??? CT abdomen and pelvis without and with IV contrast 2 ???? Tc-99m bone scan whole body 1 ??? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate *Relative Radiation Level Variant 4: Clinically established intermediate-risk prostate cancer. Staging

2016 American College of Radiology

7. Diagnosis, Staging and Treatment of Patients with Prostate Cancer

Diagnosis, Staging and Treatment of Patients with Prostate Cancer Diagnosis, staging and treatment of patients with prostate cancer National Clinical Guideline No. 8 June 2015Guideline Development Group The National Clinical Guideline on the diagnosis, staging and treatment of patients with prostate cancer in Ireland was developed by the National Cancer Control Programme (NCCP), in collaboration with clinicians, librarians and stakeholder groups. Reference of National Clinical Guideline (...) National Clinical Guideline No. 8 should be referenced as follows: Department of Health. Diagnosis, staging and treatment of patients with prostate cancer. National Clinical Guideline No. 8. June 2015. Updated March 2016. ISSN 2009-6259. National Clinical Guideline No. 8 ISSN 2009-6259. Published June 2015. Update March 2016: Removal of resource implications on Recommendations 2.7.4.2 and 2.7.5.2. Notice to Health Professionals and Disclaimer The Guideline Development Group’s expectation is that health

2016 National Clinical Guidelines (Ireland)

8. Cancer Core Length from Targeted Biopsy: An Index of Prostate Cancer Volume and Pathologic Stage. (PubMed)

Cancer Core Length from Targeted Biopsy: An Index of Prostate Cancer Volume and Pathologic Stage. To study the relationship of maximum cancer core length (MCCL), on targeted biopsy (TB) of magnetic resonance imaging (MRI)-visible index lesions, to volume of that tumour found at radical prostatectomy (RP).In all, 205 men undergoing fusion biopsy and RP were divided into two groups: 136 in whom the MCCL came from an index MRI-visible lesion (TB) and 69 in whom MCCL came from a non-targeted lesion (...) MCCLs >10 mm and Gleason scores >7 were each associated with pathological T3 disease (odds ratios 5.73 and 5.04, respectively), but MRI lesion diameter lesion was not.MCCL on a TB from an MRI-visible lesion is an independent predictor of both cancer volume and pathological stage. This relationship does not exist for MCCL from a NTB core. Quantifying CCL on MRI-TBs may have a value, not previously described, to risk-stratify patients with prostate cancer before treatment.© 2019 The Authors BJU

2019 BJU international

9. Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy (PubMed)

Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy There is growing evidence supporting incorporating multiparametric (mp) magnetic resonance imaging (MRI) scans into risk stratification, active surveillance, and treatment paradigms for prostate cancer. The purpose of our study was to determine whether demographic disparities exist in staging MRI utilization for prostate cancer patients.An (...) across all risk groups and black or nonprivate insurance patients in the low risk group were less likely to undergo staging prostate MRI scans. Further research should investigate these differences to ensure equitable utilization across all demographic groups considering the burden of prostate cancer disparities.

Full Text available with Trip Pro

2016 Advances in radiation oncology

10. Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer

Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2017 Clinical Trials

11. Prostate cancer: diagnosis and management

. Ov Overview erview This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer. Who is it for? Healthcare professionals Commissioners and providers of prostate cancer services People with prostate cancer, their families (...) pathological stage predict risk of treatment failure. [2008] [2008] 1.1.8 Explain the reliability, validity and limitations of any predictions made using nomograms. [2008] [2008] 1.1.9 Discuss all relevant management options in this guideline with people with prostate cancer and their partners or carers, even if they are not available through their local services. [2008] [2008] 1.1.10 T ell people with prostate cancer: about treatment options and their risks and benefits in an objective, unbiased manner

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

12. Comparison of diagnostic efficiencies of different types of 18F-labeled tracers in various stages of prostate cancer

Comparison of diagnostic efficiencies of different types of 18F-labeled tracers in various stages of prostate cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO

13. Prostatectomy versus radiotherapy for early-stage prostate cancer (PREPaRE) study: protocol for a mixed-methods study of treatment decision-making in men with localised prostate cancer. (PubMed)

Prostatectomy versus radiotherapy for early-stage prostate cancer (PREPaRE) study: protocol for a mixed-methods study of treatment decision-making in men with localised prostate cancer. Men diagnosed with localised prostate cancer (LPC) wanting curative treatment face a highly preference-sensitive choice between prostatectomy and radiotherapy, which offer similar cure rates but different side effects. This study aims to determine the information, decision-making needs and preferences of men

Full Text available with Trip Pro

2017 BMJ open

14. <sup>68</sup>Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. (PubMed)

68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. To systematically review currently available data on 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) used for the primary staging of high-risk prostate cancer.We performed critical reviews of EMBASE, Web of Science (including MEDLINE) and Cochrane databases in October 2016 according to the Preferred (...) Reporting Items for Systematic Review and Meta-analysis statement. We included studies that utilized 68Ga-PSMA PET for primary staging of prostate cancer. Quality was assessed using the Critical Appraisal Skills Programme checklist for diagnostic test studies.Following our systematic search strategy, 12 studies were included for assessment. These studies comprised a total of 322 patients who underwent 68Ga-PSMA PET scanning for the purpose of primary staging. Only 5 of these studies included

2018 World journal of urology

15. Impact of prostatic anterior fat pads with lymph node staging in prostate cancer (PubMed)

Impact of prostatic anterior fat pads with lymph node staging in prostate cancer Background: Several reports have revealed the presence of lymph nodes in the prostatic anterior fat pad (PAFP). To date, no study has described the characteristics of Taiwanese patients harboring PAFP lymph nodes with metastatic prostate cancer involvement. Method: Between December 2006 and May 2015, a total of 849 consecutive patients underwent robot-assisted laparoscopic radical prostatectomy with PAFP dissection (...) lymph nodes were associated with the clinical T stage, preoperative Gleason score, pathological T stage, and pathological N stage (p < 0.001). Patients with pathological seminal vesicle invasion and a higher surgical Gleason score also exhibited PAFP lymph node metastases (p < 0.005). Conclusion: Our data show that 9.0% of patients had PAFP lymph nodes and that 1.3% had prostate cancer metastases. Additionally, 0.6% of patients were upstaged because of positive metastases in PAFP lymph nodes

Full Text available with Trip Pro

2018 Journal of Cancer

16. Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer. (PubMed)

Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer. To determine the cost-effectiveness of using the Oncotype DX Genomic Prostate Score (GPS), a 17-gene expression assay that can be used to inform decisions regarding active surveillance (AS) vs immediate treatment.We developed a Markov model simulating 20-year outcomes for 65-year-old men with very low-, low-, or favorable intermediate-risk prostate cancer

2018 Urology

17. Enzalutamide for hormone-relapsed non-metastatic prostate cancer

Enzalutamide for hormone-relapsed non-metastatic prostate cancer Enzalutamide for hormone-relapsed non- Enzalutamide for hormone-relapsed non- metastatic prostate cancer metastatic prostate cancer T echnology appraisal guidance Published: 15 May 2019 www.nice.org.uk/guidance/ta580 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

18. How accurate is multi-parametric MRI for predicting prostate cancer pathology and tumour staging in the real world? - An Australian multi-centre study. (PubMed)

How accurate is multi-parametric MRI for predicting prostate cancer pathology and tumour staging in the real world? - An Australian multi-centre study. To assess the accuracy of multiparametric magnetic resonance imaging (mpMRI) for the detection of significant prostate cancer in men undergoing radical prostatectomy (RP) in an Australian multicentre setting, and to assess concordance between mpMRI and RP for local tumour staging and index lesion locations.Men who underwent mpMRI within 12 (...)  months of RP between January 2013 and August 2016 at three Australian sites were included (Central Coast, NSW, St Vincents Hospital, Melbourne, Vic., and Bendigo Hospital, Vic.). The results of mpMRI were compared with the final RP specimen to analyse the performance of mpMRI for significant prostate cancer detection, index lesion localization, prediction of T3 disease and lymph node metastasis. A comparison between mpMRI cases performed using the technical and reporting specifications of Prostate

2019 BJU international

19. The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer. (PubMed)

The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer. Local recurrent prostate cancer after radical treatment is found in the majority of men with a rising PSA. Salvage treatment procedures for recurrent disease, such as radiation therapy and ablative procedures, can provide long-term responses in well-selected cases. Prostate magnetic resonance imaging (MRI) allows diagnosis and staging, and the value provides information on treatment selection (...) , treatment planning and treatment guidance in local recurrent prostate cancer.

2019 World journal of urology

20. Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS™ version 2 Category and Staging with Whole Mount Histopathology Correlation. (PubMed)

Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS™ version 2 Category and Staging with Whole Mount Histopathology Correlation.

2019 Journal of Urology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>